ImmunoVaccine Inc.  

(Public, CVE:IMV)   Watch this stock  
Find more results for IMV
Nov 25 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range     -
52 week 0.35 - 1.50
Open     -
Vol / Avg. 0.00/147,516.00
Mkt cap 67.59M
P/E     -
Div/yield     -
EPS -0.07
Shares 90.02M
Beta 1.17
Inst. own     -
Nov 14, 2014
Q3 2014 Immunovaccine Inc Earnings Release
Oct 8, 2014
Immunovaccine Inc at BIO Investor Forum

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -58.33% -104.66%
Return on average equity -104.41% -212.79%
Employees 20 -
CDP Score - -


1344 Summer Street, Suite 412
+1-902-4921819 (Phone)
+1-902-4920888 (Fax)

Website links


Immunovaccine Inc. is a clinical stage vaccine development company. The Company is focusing its research and development on developing an early stage human health vaccine pipeline consisting of infectious diseases and therapeutic cancer vaccine products. The Company�s advanced vaccine candidate is DPX-0907, a multivalent therapeutic cancer vaccine targeting ovarian, breast and prostate cancers. During the year ended December 31, 2010, the Company was in a multi-site Phase I human clinical trial for DPX-0907 in the United States. The Company has developed a lipid depot-based vaccine delivery and enhancement technology called the DepoVax platform, an improvement on the Company�s original VacciMax platform. The Company has completed proof of concept pre-clinical studies in infectious disease applications, such as single-dose DepoVax platform-based pandemic influenza and hepatitis B vaccine candidates.

Officers and directors

Marc Mansour Ph.D. Chief Executive Officer, Director
Age: 39
Kimberly Stephens Chief Financial Officer, Corporate Secretary
Albert James Scardino Non-Executive Chairman
Age: 65
Wade K. Dawe Director
Alfred A. Smithers Director
James W. Hall Independent Director
Age: 64
Wayne F. Pisano Independent Director